Clinical and Translational

Managing Multiple Biomarker Therapeutic Development

134 views
September 12, 2019
For the past two decades, the paradigm in the field has been “one biomarker, one drug,” leading to the development of many targeted therapies and companion diagnostics. As molecular profiling of various cancer types expands, we imagine the use of multiple biomarkers for a combination therapy, like a targeted therapy and immunotherapy together, or even for a monotherapy.

In this roundtable our panelists will discuss assessing the validity of biomarkers to inform drug development and potential combination therapies. Key considerations include predictive testing of biomarkers, analytical methods, drug-diagnostic co-development and potential reimbursement considerations. Dr. Kelly Sullivan, Solutions Manager, N-of-One (a QIAGEN Company) will moderate the discussion with Jeffrey Waldron, Executive Director, Precision Medicine Connective, and Dr. Diana Merino, Science Policy Analyst at Friends of Cancer Research.


Interested in learning more?

Click here


Related videos

Clinical and Translational

Cancer Gene Variant Detection Using a Pre-Optimized Sample to Report Workflow

45 views October 30, 2019

BRCA1/BRCA2 genes represent the best examples for our current understanding...

Clinical and Translational

Better Knowledge for Better Care with QIAGEN and N-of-One: Precision medicine for any cancer...

508 views May 29, 2019

For NGS cancer testing, keeping pace with new discoveries is a serious...

Clinical and Translational

The Human Gene Mutation Database: Empowering a Generation of Geneticists for Precision Medicine

863 views April 10, 2019

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive...

Clinical and Translational

Fast tracking clinical NGS testing with QIAGEN Clinical Informatics services

46 views October 15, 2019

Discover a simpler and faster approach to implementing clinical NGS...